Smartest Doc
Comparative Effectiveness Analysis of Amlodipine/Renin-Angiotensin System Blocker Combinations
The Journal of Clinical Hypertension, 08/16/2012
Clinical Article
Ram CVS et al. – Switchers from monotherapy with antihypertensive therapy amlodipine (AML), olmesartan (OM), or valsartan (VAL) to AML/OM were significantly more likely to attain JNC 7 goals than those switching to AML/VAL or AML/benazepril (BEN).
- A comparative effectiveness analysis of antihypertensive therapy amlodipine (AML) and angiotensin receptor blocker (ARB) fixed– and loose–dose combinations (FDCs and LDCs) in achieving blood pressure (BP) reduction and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) goal attainment was made using retrospective electronic medical record (EMR) data.
- Treatment goal rates ranged from 35.0% for LDC AML/losartan to 45.7% for FDC AML/olmesartan (OM).
- FDC AML/OM achieved significantly greater reductions in systolic BP than FDC AML/benazepril (BEN), FDC AML/valsartan (VAL), and LDC AML/ARBs, respectively, and significantly greater reductions in diastolic BP than FDC AML/VAL and LDC therapy, respectively.
- Compared with patients treated with AML/OM, patients prescribed AML/VAL and LDC AML/ARB were significantly less likely to attain JNC 7 BP goal.
- Among subpopulations, AML/OM yielded higher rates of goal attainment among both African Americans and obese/overweight patients relative to AML/VAL and combined LDCs.
